{
  "actions": [
    {
      "acted_at": "2018-06-28",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2018-06-28",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr6294-115",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    }
  ],
  "congress": "115",
  "cosponsors": [
    {
      "bioguide_id": "C001097",
      "district": "29",
      "name": "C\u00c3\u00a1rdenas, Tony",
      "original_cosponsor": true,
      "sponsored_at": "2018-06-28",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "E000215",
      "district": "18",
      "name": "Eshoo, Anna G.",
      "original_cosponsor": false,
      "sponsored_at": "2018-07-24",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2018-06-28",
  "number": "6294",
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivity extension period, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Re-Valuing Anti-Microbial Products Act of 2018",
  "sponsor": {
    "bioguide_id": "S000364",
    "district": "15",
    "name": "Shimkus, John",
    "state": "IL",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2018-06-28",
  "subjects": [
    "Advisory bodies",
    "Congressional oversight",
    "Drug safety, medical device, and laboratory regulation",
    "Drug therapy",
    "Government studies and investigations",
    "Health",
    "Health promotion and preventive care",
    "Infectious and parasitic diseases",
    "Intellectual property",
    "Licensing and registrations",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2018-06-28",
    "date": "2019-08-20T18:49:34Z",
    "text": "Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a \"priority antimicrobial product.\" (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)"
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "REVAMP Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivity extension period, and for other purposes.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Re-Valuing Anti-Microbial Products Act of 2018",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "REVAMP Act",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-11T13:42:15Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/hr/BILLSTATUS-115hr6294.xml"
}